| pubmed-article:1720991 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1720991 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:1720991 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1720991 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:1720991 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1720991 | lifeskim:mentions | umls-concept:C1413236 | lld:lifeskim |
| pubmed-article:1720991 | lifeskim:mentions | umls-concept:C0205470 | lld:lifeskim |
| pubmed-article:1720991 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:1720991 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1720991 | pubmed:dateCreated | 1992-1-17 | lld:pubmed |
| pubmed-article:1720991 | pubmed:abstractText | Six patients with rheumatoid arthritis were treated with a CD7 mouse monoclonal antibody, RFT2, daily for 15 days. Only two patients had a significant improvement in clinical disease activity which lasted 7-14 days. No serious adverse effects occurred although all patients developed antibodies against mouse immunoglobulin. During treatment T-lymphocyte numbers decreased and T-lymphocyte CD7 expression was absent in all but one patient. | lld:pubmed |
| pubmed-article:1720991 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1720991 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1720991 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1720991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1720991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1720991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1720991 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1720991 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1720991 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:1720991 | pubmed:issn | 0263-7103 | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:GibsonTT | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:GrahameRR | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:AmlotP LPL | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:PanayiG SGS | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:SabharwalSS | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:PitzalisCC | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:KirkhamB WBW | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:KingsleyG HGH | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:BarbatisCC | lld:pubmed |
| pubmed-article:1720991 | pubmed:author | pubmed-author:ChikanzaI CIC | lld:pubmed |
| pubmed-article:1720991 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1720991 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:1720991 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1720991 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1720991 | pubmed:pagination | 459-63 | lld:pubmed |
| pubmed-article:1720991 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:meshHeading | pubmed-meshheading:1720991-... | lld:pubmed |
| pubmed-article:1720991 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1720991 | pubmed:articleTitle | Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody. | lld:pubmed |
| pubmed-article:1720991 | pubmed:affiliation | Rheumatology Unit, United Medical School, Guy's Hospital, London, England. | lld:pubmed |
| pubmed-article:1720991 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1720991 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1720991 | lld:pubmed |
